2X6E
Aurora-A bound to an inhibitor
Summary for 2X6E
Entry DOI | 10.2210/pdb2x6e/pdb |
Related | 1MQ4 1MUO 1OL5 1OL6 1OL7 2BMC 2C6D 2C6E 2J4Z 2J50 2W1C 2W1D 2W1E 2W1F 2W1G 2WQE 2WTV 2WTW 2X6D |
Descriptor | SERINE/THREONINE-PROTEIN KINASE 6, 6-BROMO-7-{4-[(5-METHYLISOXAZOL-3-YL)METHYL]PIPERAZIN-1-YL}-2-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-IMIDAZO[4,5-B]PYRIDINE (2 entities in total) |
Functional Keywords | transferase, mitosis, cell cycle |
Biological source | HOMO SAPIENS (HUMAN) |
Cellular location | Cytoplasm, cytoskeleton, microtubule organizing center, centrosome : O14965 |
Total number of polymer chains | 1 |
Total formula weight | 33500.26 |
Authors | Kosmopoulou, M.,Bayliss, R. (deposition date: 2010-02-17, release date: 2010-07-07, Last modification date: 2023-12-20) |
Primary citation | Bavetsias, V.,Large, J.M.,Sun, C.,Bouloc, N.,Kosmopoulou, M.,Matteucci, M.,Wilsher, N.E.,Martins, V.,Reynisson, J.,Atrash, B.,Faisal, A.,Urban, F.,Valenti, M.,de Haven Brandon, A.,Box, G.,Raynaud, F.I.,Workman, P.,Eccles, S.A.,Bayliss, R.,Blagg, J.,Linardopoulos, S.,McDonald, E. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J. Med. Chem., 53:5213-5228, 2010 Cited by PubMed: 20565112DOI: 10.1021/jm100262j PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.35 Å) |
Structure validation
Download full validation report